Sugi Predict

Sugi Predict / Targets / PRPF31

PRPF31

U4/U6 small nuclear ribonucleoprotein Prp31 · Q8WWY3 · PRPF31 on Sugi Atlas →

0 patent compounds predicted against PRPF31, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PRPF31 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001 PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects PHASE1COMPLETED
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby) PHASE1COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy nanACTIVE_NOT_RECRUITING
Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa nanCOMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Mutations and Phenotypes of Unclassifiable Inherited Bone Marrow Failure Syndromes nanRECRUITING
Genetic Investigation of Cancer Predisposition nanNOT_YET_RECRUITING
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study) nanRECRUITING
Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study nanRECRUITING
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF) nanCOMPLETED
NFC Changes in SLE Patients and Its Correlation With Anti-U1RNPAntibodies and Disease Activity nanUNKNOWN
Exome Analysis in Hearing Impaired Patients nanUNKNOWN
Biomarker Research in Inherited Movement Disorders nanRECRUITING
Identification of New FTLD Genes nanUNKNOWN
Study of Constitutional Platelet Disease nanUNKNOWN
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing nanRECRUITING
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases nanRECRUITING
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH) nanCOMPLETED
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC nanUNKNOWN
Diagnosis of Inflammatory Bowel Disease nanNOT_YET_RECRUITING
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED
Management of Retinitis Pigmentosa Via Electromagnetic Stimulation and Platelet Rich Plasma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PRPF31 binder may also engage these)

ProteinNameSimilarity
Q8CCF0 — 1.000 Q8CCF0 →
Q6NVP6 — 1.000 Q6NVP6 →
Q5U5C5 — 1.000 Q5U5C5 →
Q7SXM7 — 1.000 Q7SXM7 →
Q8RXN6 — 0.979 Q8RXN6 →
NAT10 RNA cytidine acetyltransferase 0.975 landscape →
O08837 — 0.974 O08837 →
Q2KJC1 — 0.974 Q2KJC1 →
Q8K339 — 0.974 Q8K339 →
CDC5L Cell division cycle 5-like protein 0.973 landscape →
Q6GNS3 — 0.973 Q6GNS3 →
Q8CCP0 — 0.973 Q8CCP0 →
Q9XHR2 — 0.971 Q9XHR2 →
Q6A068 — 0.970 Q6A068 →
P92948 — 0.969 P92948 →
Q3SYW6 — 0.969 Q3SYW6 →
A1A4I9 — 0.969 A1A4I9 →
Q9LD55 — 0.969 Q9LD55 →
B4HMY3 — 0.968 B4HMY3 →
B4LNA1 — 0.968 B4LNA1 →
B4KN00 — 0.968 B4KN00 →
Q9XHM1 — 0.968 Q9XHM1 →
B3MIF1 — 0.968 B3MIF1 →
Q28Z41 — 0.968 Q28Z41 →
A8MS85 — 0.968 A8MS85 →
O60870 — 0.968 O60870 →
Q6PFQ2 — 0.967 Q6PFQ2 →
EIF3C Eukaryotic translation initiation factor 3 subunit C 0.967 landscape →
B5ME19 — 0.967 B5ME19 →
B3NML0 — 0.967 B3NML0 →